Proven Before Promising

The supplement industry sells you ninety percent of what you do not need and ten percent of what you do. The influencer frontier does the opposite kind of damage, selling provisional compounds as if they were settled. This is the pillar where hype does the most harm, so it gets the strictest standard I have. Molecules runs from a basic supplement to a hormone to a prescription drug to a peptide. It is never the first thing I reach for, and never a shortcut around Meals, Movement, and Mind.

Two ideas govern everything below. The evidence grade is a dial, not a label: it runs from proven human outcome data down to honest hypothesis, and most things sit somewhere in between. And what I can hand you is a separate question from how strong the evidence is.

The grade, and what I can hand you

That second idea is the one people skip, so let me make it concrete. The grade tells you how strong the evidence is. What I can put in your hands is a different matter, of regulation and safety, and I keep that line visible. Supplements and off-label medicines I discuss openly, always with the physician partnership in frame, never as a prescription. Peptides I cover data-first, walking the commonly-spoken protocols with an honest read of the data, or its absence. Anything tuned to one specific person is the work of private coaching and a prescriber, not a public page. Anabolic steroids and the like are simply not part of this practice. You will not find dosing in this hub; it lives in the dedicated pieces and the app, where each compound is graded one at a time.

Optimized, not normal

Here is where I diverge hardest from the standard of care. A lab's normal range is a reference interval: it describes how your result compares with the lab's own reference population and the method it used, usually the middle of that group's spread. It is a statistical band, not a diagnosis, not a treatment threshold, and not your individualized target. A result inside it is not automatically healthy, and one outside it is not automatically disease. So my position is plain: I am not interested in coaching you to normal, the middle of the pack. Working with a knowledgeable physician, I coach toward optimal.

ApoB is my first worked example. ApoB, short for apolipoprotein B, is essentially the count of cholesterol-carrying particles in your blood that can lodge in an artery wall and build plaque. I track it ahead of standard LDL cholesterol because it counts those particles directly, and the evidence that it tracks risk at least as well as LDL, and in many analyses better, is good. One honest note on the guideline: the current US guideline, the 2026 ACC/AHA dyslipidemia guideline, keeps LDL and non-HDL cholesterol as the formal treatment goals and brings ApoB in selectively, to refine residual risk once those goals are met. Making ApoB my first-look target is a step beyond where the guideline goes, and I own it as my coaching position, not the guideline's. The full version, why the particle count matters, how inflammation adds its own separate risk on top, and where I set the target, lives in the ApoB deep-dive.

The principle reaches past lipids. Steady blood sugar is a longevity target, not just a diabetic one, though I will say honestly that the hardest outcome data there is in people who already have diabetes, and extending it to a healthy person is a reasonable extrapolation, not settled proof. The pattern is the same every time: aim past not-sick toward optimal, and say out loud exactly how far the evidence walks with me.

The floor: proven basics, and your own labs

The floor of this pillar is short and unglamorous: a few well-validated basics that earn their place for a specific goal, plus correcting whatever your labs show you are actually short on. If you train for strength or muscle, creatine is the cleanest example there is, one of the most-studied compounds in all of sport, effective for strength and lean mass and safe across years of use. Past that, I do not build elaborate stacks on an empty floor. Most people are over-supplemented on a dozen unproven things and under-supplemented on a few proven ones, and fixing that, from labs and not vibes and in partnership with your coach and your doctor, beats a twelve-bottle shelf every time.

Hormones: restoration and performance are the same project

The usual framing splits hormonal restoration from performance, as if they were different goals. They are the same goal. Real, diagnosed hormone deficiency drags down strength, recovery, drive, body composition, bone, metabolism, cognition, and sleep, because the same signals run all of it, and treating it under a physician is well supported. Going past the treatment of deficiency toward an individualized optimal is a broader coaching position, and I will always be clear about which is which.

Testosterone is the worked example. Hypogonadism, clinically low testosterone, means symptoms and signs of deficiency together with unequivocally and consistently low blood levels, not a single number you happen to dislike (Bhasin et al. 2018, Endocrine Society guideline). Done right, it is diagnosed properly and then monitored for the well-documented side effects, the big one being a rising hematocrit, your blood thickening with too many red cells, with prostate health watched alongside. There are also clear reasons not to start, prostate or breast cancer chief among them, and the guideline lays out the full list. The largest recent safety trial, TRAVERSE, restored deficient men at cardiovascular risk to a mid-range, physiologic level, meaning within the body's natural range, and found no increase in major cardiac events against placebo, while flagging atrial fibrillation and a couple of other signals worth watching. That is a safety finding in deficient men restored to the middle of the range. It is not evidence for an optimal level. Where I go further, in my own voice, is that I find many men feel and function best nearer the top of the range than at the level that merely clears the low flag. That is my coaching position, individualized and monitored, not a TRAVERSE finding and not a single number for everyone to chase, and the specific target gets set in the individual work, with your coach and your physician, and it lives in the testosterone deep-dives. Pushing past the top of the range into supraphysiologic territory, above the body's natural range, for performance is outside this practice. For women, perimenopause and menopause reshape the whole picture, and that hormone-therapy decision is its own informed-consent conversation, never the same one as for men.

If you run hormones or any higher-risk molecule, monitoring is non-negotiable. It catches harm early and it steers, but it does not erase uncertainty, and it does not turn an unproven or contraindicated protocol into a good idea. For testosterone the monitoring surface is not mainly lipids: it is how you feel and function, your serum testosterone, your hematocrit and hemoglobin, your fertility intentions, prostate-risk where it applies, blood pressure, and sleep apnea, set against your own contraindications. Monitoring goes up while a protocol is active, not down. This is overview, not instruction. The specifics live in dedicated pieces, in coaching, and with your physician.

The frontier, in order

Once the floors hold, the edges earn a place, best-validated first, brought in one at a time, each with a monitoring plan so I can actually read its effect against your data. Peptides are the fastest-moving corner, and I cover them data-first. A few have real human evidence, and many sit on mechanism, animal work, and honest real-world experience, so I grade them one by one and never pretend the evidence is uniform. Rapamycin sits at the emerging end. My own read is that it is the most interesting longevity signal in animal research right now, with the human case still wide open, and I am watching it closely. Metformin I put as solid for blood sugar and unproven for longevity. Both of those are my read of a fast-moving field rather than settled claims, and each is getting its own dedicated piece where I will lay out the evidence as it actually stands.

I want to be clear about something here, because the floor-first discipline can read as caution. I do reach these edges, and I use some of them myself. The discipline is about order, not avoidance: base before edge, one at a time, data in view. The grade is a dial, and that is what lets me take the frontier seriously without letting it run the plan.

One rule sits above all of it: never knowingly introduce molecules that might cause irreversible harm, no matter how good the upside looks on paper. I cannot promise zero risk from anything, but I can refuse the bets where the irreversible harm is real and unjustified, and define the monitoring and the stopping rules before I start. My standing example is the corticosteroid injection. It is a broad category, and the tradeoffs depend on where it goes, what tissue is involved, how often it is used, and what procedure might follow. In some musculoskeletal settings the evidence raises real concerns, about tissue effects or worse later surgical outcomes, but those risks belong to the specific setting where they were studied, not to every injection everywhere. My own version of this was turning down a corticosteroid injection in my back, during the worst pain of my life. That was my decision about a spinal problem, and I tell the full story over in The Floor I Built From. Everything at the frontier answers to the same rule: monitored, reversible, and worth a clearly defined risk. Never on faith, never on marketing.

Get the right physician on your team

Most of Molecules depends on having the right physician on your team, and part of my job as your coach is to help you find one and integrate them well. The familiar failure mode is a rushed visit, a basic panel, an "everything looks fine," and then nothing changes. The right physician works differently. They practice integrative, whole-person medicine, they look past the bare minimum, and they choose the right tests for the person in front of them instead of running everything on everyone, things like ApoB and Lp(a), fasting insulin, hs-CRP (high-sensitivity C-reactive protein, a blood marker of inflammation), or a fuller thyroid and hormone picture when the situation calls for it. They will actually engage with evidence-based off-label options instead of waving them off. They use imaging when it is warranted, a coronary calcium score or a DEXA. And they treat you as a collaborator in an informed-consent decision, not a passive recipient. Here is the line I hold. They handle the medicine, the medical guidance, and the prescribing. I handle the coaching, I coach the whole person, and I help you fit the two together. This is a coaching practice, not a medical one, and I respect the physician's role precisely because it is theirs. A good physician is an essential teammate, and a physician is not your coach. I am fortunate to work closely with a number of physicians and practices who lead in integrative and longevity medicine. I see some of them myself, and I help my clients find and work well with the right ones.

The red flags are as useful as the green ones, so be wary of a clinic attached to its own supplement store or selling its own branded labs. This kind of care often is not covered by insurance, which is a real access barrier, and I will say plainly that where you cannot reach it, the floors of all four pillars still deliver most of the result on their own.

The honest take

The supplement industry sells you ninety percent of what you do not need, and the influencer frontier sells the provisional as if it were proven. Here is the honest version. A short list of well-evidenced basics, plus correcting your measured deficiencies, beats a twelve-bottle shelf. The genuinely promising frontier is worth honest curiosity, but it is not settled, and it belongs in coaching and with your physician. Any molecule that cannot be monitored, reversed, and justified by a defined risk does not earn a place at all. And the target is optimal, not normal, reached with a coach and a doctor who measures, because sitting inside the lab's range only means you have not been flagged, and not-flagged is not where I want you to live. That is the Molecules pillar of Balanced Longevity™: proven before promising, monitored and reversible, always with your team.

Evidence

Highest evidence grade in this article: A · Proven. Each claim below is graded on its own; a high grade for one does not carry to the others.

• ApoB tracks cardiovascular risk at least as well as, and in many analyses better than, standard LDL cholesterol (Sniderman et al. 2019): C · Moderate. A biomarker comparison resting on observational and Mendelian-randomization evidence, which caps it at C, and the marker-comparison methodology is still debated. For current guidance: the 2026 ACC/AHA dyslipidemia guideline keeps LDL-C and non-HDL-C as the formal treatment goals and positions ApoB as a selective tool to refine residual risk once those goals are met, particularly with high triglycerides, diabetes, or low achieved LDL-C (Blumenthal et al. 2026). Making ApoB my first-look target is a step beyond the guideline, owned as my coaching position.
• ApoB-containing lipoproteins are causally responsible for atherosclerosis, and their retention in the artery wall initiates the inflammation that builds plaque, so lowering ApoB is foundational (Borén et al. 2020, European Atherosclerosis Society consensus): A · Proven. Genetic, epidemiologic, and randomized evidence converge on causality; this is the settled model, which is why the mechanism is stated as established rather than as my own claim.
• Reducing inflammation lowers cardiovascular events independent of cholesterol, so inflammation adds its own residual risk on top of the lipid-driven disease, which is why ApoB is necessary but not sufficient (Ridker et al. 2017, CANTOS): B · Strong. Large randomized trial proving the principle; the effect was modest, there was no all-cause mortality benefit, and the drug itself is not used clinically for this, so the takeaway is that inflammation is a real, separate lever alongside ApoB, not that it must precede particle retention.
• Creatine improves strength and lean mass and is safe across years of use (Kreider et al. 2017, ISSN position stand): B · Strong. Large independent literature; note the position stand has industry-adjacent authorship, so the grade rests on the broader evidence base.
• Restoring low testosterone to a mid-range physiologic level did not increase major adverse cardiac events versus placebo in hypogonadal men at cardiovascular risk (Lincoff et al. 2023, TRAVERSE): B · Strong. This is a safety finding in deficient men restored to the middle of the range. It is not evidence for an optimal level or for raising men to the high end; the higher-end-of-range position I describe is my coaching position, individualized and monitored, not a trial finding. The specific target lives in the testosterone deep-dives, set in coaching and watched with a physician. Signals worth monitoring: atrial fibrillation, acute kidney injury, pulmonary embolism. For diagnosis, contraindications, and the monitoring surface (symptoms plus consistently low levels; hematocrit; prostate and sleep-apnea cautions), I follow the Endocrine Society clinical practice guideline (Bhasin et al. 2018): professional consensus guidance, treated as the default standard of care around which the optimal-range position is individualized.
• Greater glycemic variability tracks with higher cardiovascular risk and mortality (Gorst et al. 2015): C · Moderate. Strong within diabetic populations; extending it to glucose optimization in metabolically healthy people is a reasonable extrapolation, not settled proof, so graded modestly.

Sources

• Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiology. 2019;4(12):1287-1295. https://doi.org/10.1001/jamacardio.2019.3780
• Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia. Journal of the American College of Cardiology. Published online March 13, 2026. https://doi.org/10.1016/j.jacc.2025.11.016
• Borén J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal. 2020;41(24):2313-2330. https://doi.org/10.1093/eurheartj/ehz962
• Ridker PM, Everett BM, Thuren T, et al.; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine. 2017;377(12):1119-1131. https://doi.org/10.1056/NEJMoa1707914
• Kreider RB, Kalman DS, Antonio J, et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. Journal of the International Society of Sports Nutrition. 2017;14:18. https://doi.org/10.1186/s12970-017-0173-z
• Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. New England Journal of Medicine. 2023;389(2):107-117. https://doi.org/10.1056/NEJMoa2215025
• Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2018;103(5):1715-1744. https://doi.org/10.1210/jc.2018-00229
• Gorst C, Kwok CS, Aslam S, et al. Long-term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review and Meta-analysis. Diabetes Care. 2015;38(12):2354-2369. https://doi.org/10.2337/dc15-1188